Cost Considerations for Monoclonal Antibody-Targeted Therapy in Cancer: Focus on Trastuzumab

Author： Neyt Mattias  

Publisher： Adis International

ISSN： 1175-6357

Source： American Journal of Cancer, Vol.5, Iss.1, 2006-01, pp. : 19-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal Antibody-Based Targeted Therapy in Breast Cancer

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 2, 2005-03 ,pp. : 99-106

Bentham Science Publishers

Access to resources Recommend Favorite

Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1

By            

Oncology Reports, Vol. 31, Iss. 3, 2014-01 ,pp. : 1059-1066

Spandidos Publications

Access to resources Recommend Favorite

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias   Wilking Nils   Jonsson Bengt   Rehnberg Clas  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when

By Olver Ian N  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 125-131

Future Medicine

Access to resources Recommend Favorite